Abridge received investment from Eli Lilly as it expands from clinical documentation into clinical trial recruitment workflows. Lilly’s venture arm is backing the startup as it broadens its life-sciences reach, with the investment aimed at optimizing how sponsors identify and engage eligible trial participants. The expansion reflects intensifying competition among clinical AI vendors as recruitment and enrollment timelines become key operational bottlenecks. By adding recruitment capabilities to its existing platform, Abridge is positioning itself for more end-to-end trial support across sponsor and site workflows. For biotech operators, the move may translate to faster screening, improved patient matching, and better operational predictability—areas that increasingly determine trial execution success.